First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

作者
Qiang Wu,Wuxia Luo,Wen Li,Ting I. Wang,Lin Huang,Feng Xu
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:11: 598265-598265 被引量:44
标识
DOI:10.3389/fonc.2021.598265
摘要

OBJECTIVE: The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy (CT) compared to EGFR-TKI monotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutation. METHODS: A systematic literature search of randomized controlled trials using Cochrane Library, PubMed, Embase, and Web of Science, was performed up to Jan. 7th, 2020. Hazard ratios (HRs) with 95% confidence intervals (CI) were calculated as effect values for progress-free survival (PFS) and overall survival (OS). Risk ratio (RR) and Odds ratio (OR) were calculated as effect values for objective response rate (ORR) and toxicity, respectively. RESULTS: A total of eight randomized trials involving 1,349 advanced NSCLC patients with sensitive EGFR mutation were included in the meta-analysis. All patients in both groups received first-generation TKI as first-line treatment. The pooled HR of PFS and OS was 0.56 (95% CI = 0.50-0.64; P <0.00001) and 0.70 (95% CI = 0.54-0.90; P = 0.005), respectively. Subgroup analysis showed significantly higher OS advantages in patients receiving doublet CT (P = 0.02) and concurrent therapy (P = 0.002). The ORR in the EGFR-TKI plus CT group was significantly higher than in the EGFR-TKI monotherapy group (RR = 1.18, 95% CI = 1.10-1.26). The combination regimen showed a higher incidence of chemotherapy-induced toxicities. Subgroup analysis indicated that doublet chemotherapy rather than single-agent chemotherapy significantly increased incidence of grade 3 or higher leukopenia, neutropenia and anemia. CONCLUSIONS: Compared with EGFR-TKI monotherapy, the combination of first-generation EGFR-TKI and CT, especially when applying concurrent delivery of platinum-based doublet chemotherapeutic drugs, significantly improve ORR and prolong PFS and OS in first-line treatment for advanced EGFR-mutated NSCLC. Although increasing incidence of chemotherapy-induced toxicities occurs in the combination group, it is well tolerated and clinically manageable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水弘完成签到 ,获得积分10
刚刚
刚刚
风止月独徊完成签到,获得积分10
刚刚
风中茗完成签到,获得积分20
1秒前
解洙完成签到 ,获得积分10
1秒前
bkagyin的应助被武陵济世采纳,获得30
1秒前
沉静的弼发布了新的文献求助10
1秒前
1秒前
1秒前
zwjhbz完成签到,获得积分10
2秒前
2秒前
2秒前
QDU的应助被海上森林的一只猫采纳,获得10
2秒前
ding的应助被Zhang采纳,获得10
2秒前
2秒前
2秒前
微义完成签到,获得积分10
3秒前
张浩然完成签到,获得积分10
3秒前
wyh完成签到,获得积分10
3秒前
3秒前
单独完成签到,获得积分10
3秒前
3秒前
酒辞完成签到,获得积分10
3秒前
4秒前
wangzhewwe完成签到,获得积分10
4秒前
幸运雨点完成签到,获得积分10
4秒前
4秒前
明理夏槐完成签到,获得积分10
4秒前
伊面加煎蛋完成签到,获得积分10
4秒前
关月明发布了新的文献求助10
4秒前
ljx完成签到 ,获得积分10
4秒前
科研狗的春天完成签到 ,获得积分10
4秒前
4秒前
wangwei完成签到 ,获得积分10
4秒前
5秒前
orixero的应助被star采纳,获得10
5秒前
王淑芬儿完成签到 ,获得积分10
5秒前
凯旋侯完成签到,获得积分10
5秒前
5秒前
英姑的应助被yuan采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253